José Chang

1.4k total citations
17 papers, 610 citations indexed

About

José Chang is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, José Chang has authored 17 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Hematology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in José Chang's work include Cancer Treatment and Pharmacology (6 papers), Erythropoietin and Anemia Treatment (5 papers) and Neutropenia and Cancer Infections (4 papers). José Chang is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Erythropoietin and Anemia Treatment (5 papers) and Neutropenia and Cancer Infections (4 papers). José Chang collaborates with scholars based in Canada, United States and United Kingdom. José Chang's co-authors include Félix Couture, Catherine Y. Lau, Scott Young, Daniel Rayson, Karen A. Gelmon, George Dranitsaris, Mark Vincent, Kathleen I. Pritchard, Lawrence Panasci and L. Mauriac and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

José Chang

17 papers receiving 597 citations

Peers

José Chang

ONCOL

PRM

HEMAT

GENET

Burkhard Otremba Germany

J. Crawford United States

Süleyman Alıcı Türkiye

G Morack Germany

H. B. Muss United States

Ji Hyun Lee South Korea

G Martz Switzerland

N Yamaguchi Brazil

Monique Steijaert Netherlands

M. Coviello Italy

Burkhard Otremba Germany

José Chang

234 ×0.6

ONCOL

133 ×0.7

PRM

188 ×1.1

HEMAT

48 ×0.5

GENET

48 ×0.6

GENET

Citations per year, relative to José Chang José Chang (= 1×) peers Burkhard Otremba

Countries citing papers authored by José Chang

Since Specialization

Citations

This map shows the geographic impact of José Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Chang more than expected).

Fields of papers citing papers by José Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Chang. The network helps show where José Chang may publish in the future.

Co-authorship network of co-authors of José Chang

This figure shows the co-authorship network connecting the top 25 collaborators of José Chang. A scholar is included among the top collaborators of José Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Chang. José Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Lemonde, Manon, et al.. (2021). Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic. SHILAP Revista de lepidopterología. 8. 652542502–652542502. 3 indexed citations

Barboza, Miguel A., et al.. (2016). Safety of Dual Antiplatelet Therapy After Carotid Endarterectomy for Prevention of Restenosis: A Single Center Experience.. PubMed. 9(2). 5–9. 5 indexed citations

Láng, István, R. Bell, R.I. Lopez, et al.. (2013). Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial. Clinical Oncology. 26(2). 81–89. 24 indexed citations

Bormanis, Janis, Ian Quirt, José Chang, et al.. (2013). Erythropoiesis-stimulating agents (ESAs): Do they still have a role in chemotherapy-induced anemia (CIA)?. Critical Reviews in Oncology/Hematology. 87(2). 132–139. 7 indexed citations

Chan, Kelvin, et al.. (2012). Less Than Ideal: How Oncologists Practice With Limited Drug Access. Journal of Oncology Practice. 8(3). 190–195. 10 indexed citations

Pritchard, Kathleen I., Janusz Rolski, Zsuzsanna Pápai, et al.. (2010). Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Research and Treatment. 123(2). 453–461. 70 indexed citations

Capri, Giuseppe, José Chang, Pierfranco Conté, et al.. (2009). An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of Oncology. 21(3). 474–480. 64 indexed citations

Fan, Helen G. Mar, et al.. (2008). The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psycho-Oncology. 18(2). 156–161. 42 indexed citations

Dranitsaris, George, et al.. (2008). Identifying Patients at High Risk for Neutropenic Complications During Chemotherapy for Metastatic Breast Cancer With Doxorubicin or Pegylated Liposomal Doxorubicin. American Journal of Clinical Oncology. 31(4). 369–374. 23 indexed citations

10.

Dranitsaris, George, et al.. (2007). The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Research and Treatment. 107(3). 443–450. 48 indexed citations

11.

Quirt, Ian, Michael J. Kovacs, Félix Couture, et al.. (2006). Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience. The Oncologist. 11(1). 73–82. 8 indexed citations

12.

Chang, José, et al.. (2005). A phase II randomized trial of three loading doses of epoetin alfa followed by every three-week (q3w) dosing in cancer patients receiving chemotherapy. Journal of Clinical Oncology. 23(16_suppl). 8219–8219. 2 indexed citations

13.

Chang, José, et al.. (2004). Weekly Administration of Epoetin Alfa Improves Cognition and Quality of Life in Patients with Breast Cancer Receiving Chemotherapy. PubMed. 2(1). 52–58. 19 indexed citations

14.

Hudis, Clifford A., Simon Van Belle, José Chang, & Karsten Muenstedt. (2004). rHuEPO and Treatment Outcomes: the Clinical Experience. The Oncologist. 9(S5). 55–69. 17 indexed citations

15.

Chang, José, et al.. (2004). Weekly Epoetin Alfa Maintains Hemoglobin, Improves Quality of Life, and Reduces Transfusion in Breast Cancer Patients Receiving Chemotherapy. Journal of Clinical Oncology. 23(12). 2597–2605. 138 indexed citations

16.

Cantin, Jacques, José Chang, R. Guévin, et al.. (2002). Phase III Trial Comparing Granulocyte Colony-Stimulating Factor to Leridistim in the Prevention of Neutropenic Complications in Breast Cancer Patients Treated with Docetaxel/Doxorubicin/Cyclophosphamide: Results of the BCIRG 004 Trial. Clinical Breast Cancer. 3(4). 268–275. 37 indexed citations

17.

Chang, José. (2000). Chemotherapy dose reduction and delay in clinical practice. European Journal of Cancer. 36. 11–14. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact